Obtenga las últimas noticias sobre las acciones de Emergent BioSolutions con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de EBS

Últimas noticias sobre

EMERGENT BIOSOLUTIONS INC

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

News

Press Releases

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

General

Emergent BioSolutions Announces Addition to Russell 3000® Index

Health Care

Contracts

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Earnings

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

COLL

NTRB

NTRBW

TEVA

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

aTyr Pharma

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Erasca

Gossamer Bio

ITeos Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Kura Oncology

Myriad Genetics

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Regenxbio

Rezolute

Solid Biosciences

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Verastem

Xencor

HC Wainwright & Co.

Benchmark

Rodman & Renshaw

Chardan Capital

Screenshot 2025-03-19 at 8.55.22 PM

Biotech

BVNKF

TNXP

As Mpox Cases Spread Around The World, Tonix Pharmaceuticals&#39; Single-Dose Vaccine TNX-801 Has Potential To Slow The Spread

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Comments

Emergent BioSolutions Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL